Adjusted relative risks reduced for non-COVID-19 mortality after receipt of Pfizer-BioNTech, Moderna, Janssen vaccines<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Oct. 25, 2021 (HealthDay News) — COVID-19 vaccine recipients do not have an increased risk for non-COVID-19 mortality, according to research published in the Oct. 22 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report<\/em>.<\/p>\n Stanley Xu, Ph.D., from Kaiser Permanente Southern California in Pasadena, and colleagues examined mortality not associated with COVID-19 after COVID-19 vaccination in a general population setting. The study was conducted among about 11 million persons from seven Vaccine Safety Datalink (VSD) sites during December 2020 to July 2021.<\/p>\n The researchers found that COVID-19 vaccine recipients had lower non-COVD-19 mortality than unvaccinated persons after standardizing mortality rates by age and sex. The adjusted relative risk (aRR) of non-COVID-19 mortality for the Pfizer-BioNTech vaccine was 0.41 and 0.34 after doses 1 and 2, respectively, after adjustment for demographic characteristics and VSD site. For the Moderna vaccine, the aRRs were 0.34 and 0.31 after doses 1 and 2, respectively. After receipt of the Janssen vaccine, the aRR was 0.54.<\/p>\n “There is no increased risk for mortality among COVID-19 vaccine recipients,” the authors write. “This finding reinforces the safety profile of currently approved COVID-19 vaccines in the United States.”<\/p>\n Several authors disclosed financial ties to the biopharmaceutical industry.<\/p>\n